Other Information
−Removed: During the three months ended June 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).
+Added: On August 12, 2025 , Daniel T.
+Added: Scavilla , former President and Chief Executive Officer , terminated a Rule 10b5-1 Trading Plan.
+Added: Scavilla’s Rule 10b5-1 Trading Plan, had a term ending upon the earlier of December 31, 2025 or the sale of all shares subject to the plan.
+Added: At the time of termination, the sale of 80,000 shares of Class A common stock remained authorized under the plan.
+Added: On August 25, 2025 , Kyle R.
+Added: Kline , Chief Financial Officer and Senior Vice President , adopted a Rule 10b5-1 Trading Plan.
+Added: Kline’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of November 30, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 29,324 stock options pursuant to the terms of the plan.
+Added: Kline’s Rule 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: On September 12, 2025 , Leslie V.
+Added: Norwalk , Member of the Board of Directors , adopted a Rule 10b5-1 Trading Plan.
+Added: Norwalk’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of September 11, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 8,000 shares of Class A common stock pursuant to the terms of the plan.
+Added: Norwalk’s Rule 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act.
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q.
1 unchanged sentence
For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated in parentheses.
−Removed: Agreement and Plan of Merger, dated as of February 6, 2025, by and among Nevro Corp., Globus Medical, Inc.
−Removed: and Palmer Merger Sub, Inc.
−Removed: (incorporated by reference to Exhibit 2.1 to Globus’s Current Report on Form 8-K filed on February 6, 2025).
−Removed: 2021 Equity Incentive Plan as amended (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on June 5, 2025).
−Removed: Guaranty, dated as of September 27, 2023, by and among U.S.
−Removed: Bank National Associations, as administrative agent, and Nevro Corp., as guarantors (incorporated herein by reference to Exhibit 2.1 to Globus's Current Report on Form 8-K filed with the SEC on February 6, 2025).
Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
GLOBUS MEDICAL, INC.
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ KEITH PFEIL
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ KYLE KLINE
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.